The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Open accessAbstract
Introduction: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. Methods: Cutoffs for Elecsys amyloid‐β 1–42 (Aβ), total tau/Aβ(1–42), and phosphorylated tau/Aβ(1–42) were defined against [18 F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [18 F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied. Results: CSF total tau/Aβ(1–42) and phosphorylated tau/Aβ(1–42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer's Disease Neuroimaging Initiative (overall percent agreement: 89%–90%; area under the curves: 96%) and predicted greater 2‐year clinical decline in patients with mild cognitive impairment. Strikingly, tau/Aβ ratios were as accurate as semiquantitative PET image assessment in predicting visual read–based outcomes. Discussion: Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, the FDA-approved Elecsys CSF p-tau181/Aβ42 test has, in previous studies, classified Aβ PET status with overall accuracies of 89–90% (refs. 39–41), which was replicated in the present study.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [39]
Experimental — accuracy not yet measuredIn the citing paper
“An extracellular deposition of amyloid-β (Aβ) protein and aggregated form of hyper phosphorylated tau protein in the brain are two main pathological characteristics of AD [41].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [41]
In the citing paper
“For example, for the Elecsys immunoassays (Roche Diagnostics), it has been shown that CSF cutoffs established in one European cohort could be applied to another independent cohort in the United States to determine amyloid PET status with high accuracy.24”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [24]
In the citing paper
“Recently, fully automated immunoassays have been developed by several different vendors with improved reliability and precision for CSF Aβ and tau species.23,24,25”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [24]
In the citing paper
“This robust result is similar to what has been shown when using the Elecsys assays for CSF to establish a cutoff in one cohort and replicating it in a second cohort.24”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [24]
In the citing paper
“Plasma tau increased the AUC slightly, and provided a better model fit (ΔAIC –27), but clinically this is not comparable with the contribution CSF tau has combined with CSF Aβ42,24 and improved plasma tau assays are probably needed in the future, such as measurement of specifically phosphorylated tau,46 to increase the added value of plasma tau to plasma Aβ42 and Aβ40.”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationAlbert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,643
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 809
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J. L., Blennow, K., Johnson, K. A., Keeley, M. B., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P. S. S., & Vellas, B. J. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.14 · Cited by 72
Self-citationIncreasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Mattsson, N., Palmqvist, S., Blennow, K., & Hansson, O. (2020) · Nature Communications · doi:10.1038/s41467-020-19957-6 · Cited by 70
Self-citationStaging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
Chen, S.-D., Lu, J.-Y., Li, H.-Q., Yang, Y.-X., Jiang, J.-H., Cui, M., Zuo, C.-T., Tan, L., Dong, Q., Yu, J.-T., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01602-5 · Cited by 71
Self-citationMorris, J. C., Weiner, M., Xiong, C., Beckett, L., Coble, D., Saito, N., Aisen, P. S., Allegri, R., Benzinger, T. L. S., Berman, S. B., et al. (2022) · Brain · doi:10.1093/brain/awac181 · Cited by 68
Self-citationShen, X., Huang, Y., Chen, S.-D., Guo, Y., Tan, L., Dong, Q., Yu, J., Initiative, A. D. N., Weiner, M. W., Aisen, P., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01709-9 · Cited by 74
Self-citationLeuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 73
Self-citationAmft, M., Ortner, M., Eichenlaub, U., Goldhardt, O., Diehl‐Schmid, J., Hedderich, D. M., Yakushev, I. Y., & Grimmer, T. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01003-w · Cited by 69
Self-citationAnthocyanins Potentially Contribute to Defense against Alzheimer’s Disease
Afzal, M., Redha, A., & Al-Hasan, R. H. (2019) · Molecules · doi:10.3390/molecules24234255 · Cited by 71
Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease
Toyos‐Rodríguez, C., Alonso, F. J. G., & de la Escosura‐Muñiz, A. (2020) · Sensors · doi:10.3390/s20174748 · Cited by 69
Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline
Thomas, K. R., Osuna, J., Weigand, A. J., Edmonds, E. C., Clark, A. L., Holmqvist, S. L., Cota, I. H., Wierenga, C. E., Bondi, M. W., Bangen, K. J., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20935171 · Cited by 68
Self-citationWang, Y., Chen, J., Du, Z., Weng, H., Zhang, Y., Li, R., Jia, Z., Sun, M., Jiang, J., Wang, F.-Z., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.695696 · Cited by 64
Self-citationFirst amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
Boulo, S., Kuhlmann, J., Andréasson, U., Brix, B., Venkataraman, I., Herbst, V., Rutz, S., Manuilova, E., Vandijck, M. L. J., Dekeyser, F., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12145 · Cited by 65
Self-citationModeste, E. S., Ping, L., Watson, C. M., Duong, D. M., Dammer, E. B., Johnson, E. C. B., Roberts, B. R., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00638-z · Cited by 66
Spatial navigation ability predicts progression of dementia symptomatology
Levine, T. F., Allison, S. L., Stojanovic, M., Fagan, A. M., Morris, J. C., & Head, D. M. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12031 · Cited by 62
Guo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 67
Self-citationLongitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
Chen, S.-D., Huang, Y., Shen, X., Guo, Y., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01476-7 · Cited by 64
Self-citationWillemse, E. A. J., Tijms, B. M., van Berckel, B. N. M., Bastard, N. L., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12182 · Cited by 62
Cumplido‐Mayoral, I., García-Prat, M., Operto, G., Falcón, C., Shekari, M., Cacciaglia, R., Milà‐Alomà, M., Lorenzini, L., Ingala, S., Wink, A. M., et al. (2023) · eLife · doi:10.7554/elife.81067 · Cited by 74
Self-citationLehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00696-1 · Cited by 62
Self-citationRubinski, A., Franzmeier, N., Neitzel, J., Ewers, M., & (ADNI), T. A. D. N. I. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00702-6 · Cited by 67
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 78
The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging
Fantoni, E., Collij, L. E., Alves, I. L., Buckley, C. J., & Farrar, G. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235879 · Cited by 65
Watson, C. M., Dammer, E. B., Ping, L., Duong, D. M., Modeste, E. S., Carter, E. K., Johnson, E. C. B., Levey, A. I., Lah, J. J., Roberts, B. R., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02158-3 · Cited by 59
A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
Aksman, L., Oxtoby, N. P., Scelsi, M. A., Wijeratne, P. A., Young, A. L., Alves, I. L., Collij, L. E., Vogel, J. W., Barkhof, F., Alexander, D. C., et al. (2023) · Brain · doi:10.1093/brain/awad232 · Cited by 69
Self-citationFranzmeier, N., Dehsarvi, A., Steward, A., Biel, D., Dewenter, A., Roemer, S. N., Wagner, F., Groß, M., Brendel, M., Moscoso, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44374-w · Cited by 63
Self-citationLim, A. S. P., Gaiteri, C., Yu, L., Sohail, S., Swardfager, W., Tasaki, S., Schneider, J. A., Paquet, C., Stuss, D. T., Masellis, M., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002647 · Cited by 60
Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis
Leuzy, A., Savitcheva, I., Chiotis, K., Lilja, J., Andersen, P., Bogdanović, N., Jelić, V., & Nordberg, A. K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04297-5 · Cited by 60
Biofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives
Huang, S., Wang, Y., & Guo, J. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00836-7 · Cited by 63
Orellana, A., García‐González, P., Valero, S., Montrreal, L., de Rojas, I., Hernández, I., Rosende‐Roca, M., Vargas, L., Tartari, J. P., Antonio, E. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136891 · Cited by 57
Shanks, H. R. C., Chen, K., Reiman, E. M., Blennow, K., Cummings, J. L., Massa, S. M., Longo, F. M., Börjesson‐Hanson, A., Windisch, M., & Schmitz, T. W. (2024) · Nature Medicine · doi:10.1038/s41591-024-02977-w · Cited by 64
Self-citationFluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
Self-citationKang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Self-citationBiosensors on the road to early diagnostic and surveillance of Alzheimer's disease
Carneiro, P., Morais, S., & Pereira, M. D. C. (2020) · Talanta · doi:10.1016/j.talanta.2019.120700 · Cited by 59
Shen, X., Li, J., Wang, H., Li, H., Huang, Y., Yang, Y., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12104 · Cited by 57
Self-citationJack, C. R., Therneau, T. M., Lundt, E. S., Wiste, H. J., Mielke, M. M., Knopman, D. S., Graff‐Radford, J., Lowe, V. J., Vemuri, P., Schwarz, C. G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac017 · Cited by 59
Lehmann, S., Gabelle, A., Duchiron, M., Busto, G. U., Morchikh, M., Delaby, C., Hirtz, C., Mondésert, E., Cristol, J., Barnier-Figue, G., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105805 · Cited by 58
Yang, Z., Wen, J., Abdulkadir, A., Cui, Y., Erus, G., Mamourian, E., Melhem, R., Srinivasan, D., Govindarajan, S. T., Chen, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44271-2 · Cited by 55
Towards a unified protocol for handling of CSF before β-amyloid measurements
Janelidze, S., Stomrud, E., Brix, B., & Hansson, O. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0517-9 · Cited by 54
Self-citationInitiative, A. D. N., Canevelli, M., Arisi, I., Bacigalupo, I., Arighi, A., Galimberti, D., Vanacore, N., D’Onofrio, M., Cesari, M., & Bruno, G. (2020) · GeroScience · doi:10.1007/s11357-020-00293-y · Cited by 53
Self-citationAge-related and amyloid-beta-independent tau deposition and its downstream effects
Wuestefeld, A., Binette, A. P., Berron, D., Spotorno, N., van Westen, D., Stomrud, E., Mattsson, N., Strandberg, O. T., Smith, R. A., Palmqvist, S., et al. (2023) · Brain · doi:10.1093/brain/awad135 · Cited by 58
Self-citationKrell‐Roesch, J., Rakuša, M., Syrjanen, J. A., van Harten, A. C., Lowe, V. J., Jack, C. R., Kremers, W. K., Knopman, D. S., Stokin, G. B., Petersen, R. C., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12557 · Cited by 51
Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease
Kurz, C., Stöckl, L., Schrurs, I., Suridjan, I., Guersel, S., Bittner, T., Jethwa, A., & Perneczky, R. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15757 · Cited by 51
Self-citationAssociation of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults
Guo, T., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010596 · Cited by 51
Self-citationObrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 51
Self-citationMoscoso, A., Karikari, T. K., Grothe, M. J., Ashton, N. J., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., & Schöll, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12570 · Cited by 50
Self-citationProspective biomarkers of Alzheimer’s disease: A systematic review and meta-analysis
Li, R., Ma, Y., Tan, L., & Yu, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101699 · Cited by 54
Wang, Y., Therriault, J., Servaes, S., Tissot, C., Rahmouni, N., Macedo, A. C., Arias, J. F., Mathotaarachchi, S. S., Benedet, A. L., Stevenson, J., et al. (2023) · Brain · doi:10.1093/brain/awad397 · Cited by 54
Self-citationBucci, M., Savitcheva, I., Farrar, G., Salvadó, G., Collij, L., Doré, V., Gispert, J. D., Gunn, R., Hanseeuw, B., Hansson, O., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05311-5 · Cited by 50
Self-citationFiorenzato, E., Biundo, R., Cecchin, D., Frigo, A. C., Kim, J., Weis, L., Strafella, A. P., & Antonini, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180390 · Cited by 48
Kang, M. S., Aliaga, A., Shin, M., Mathotaarachchi, S. S., Benedet, A. L., Pascoal, T. A., Therriault, J., Chamoun, M., Savard, M., Devenyi, G. A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0818-1 · Cited by 47
Self-citationPromising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update
Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.4.401 · Cited by 47
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 52
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, M. W., Kanoria, S., Miller, M. J., Aisen, P. S. S., Beckett, L. A., Conti, C., Diaz, A., Flenniken, D., Green, R. C., Harvey, D. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14321 · Cited by 54
Self-citationBlennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46
Self-citationMüller, E. G., Edwin, T. H., Stokke, C., Navelsaker, S. S., Babovic, A., Bogdanović, N., Knapskog, A., & Revheim, M. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221365 · Cited by 48
The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA‐Q)
Belleville, S., LeBlanc, A. C., Kergoat, M., Calon, F., Gaudreau, P., Sébastien, H., Hudon, C., Leclerc, N. M., Mechawar, N., Duchesne, S., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.07.003 · Cited by 50
Complement component C4 levels in the cerebrospinal fluid and plasma of patients with schizophrenia
Gallego, J. A., Blanco, E. A., Morell, C., Lencz, T., & Malhotra, A. K. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00867-6 · Cited by 47
Dakterzada, F., Ortega, R. L., Arias, A. M., Llena, I. R., Ruiz-Julián, M., Huerto, R. P., Tahan, N., & Piñol‐Ripoll, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.604119 · Cited by 47
Association of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline
Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson, N., Hansson, O., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000013228 · Cited by 47
Self-citationSalvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12907 · Cited by 46
Self-citationLiang, S., Liu, H., Wang, X., Lin, H., Zheng, L., Zhang, Y., Peng, L., Huang, S., & Chen, L. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111263 · Cited by 50
Arslan, B., Brum, W. S., Pola, I., Therriault, J., Rahmouni, N., Stevenson, J., Servaes, S., Tan, K., Vitali, P., Montembeault, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01692-z · Cited by 61
Self-citationPTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients
Wang, H.-Y., Pei, Z., Lee, K.-C., Lopez‐Brignoni, E., Nikolov, B., Crowley, C., Marsman, M. R., Barbier, R., Friedmann, N., & Burns, L. H. (2020) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.6 · Cited by 46
Tao, Q., Alvin Ang, T. F., Akhter-Khan, S. C., Itchapurapu, I. S., Killiany, R., Zhang, X., Budson, A. E., Turk, K. W., Goldstein, L., Mez, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012512 · Cited by 45
Self-citationA head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Anastasi, F., Fernández‐Lebrero, A., Ashton, N. J., Ortiz‐Romero, P., Torres‐Torronteras, J., González‐Escalante, A., Milà‐Alomà, M., Contador, J., García‐Escobar, G., Manero-Borràs, R. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14609 · Cited by 49
Self-citationSchmitz, T. W., Soreq, H., Poirier, J., & Spreng, R. N. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1184-19.2019 · Cited by 47
Weigand, A. J., Bondi, M. W., Thomas, K. R., Campbell, N. L., Galasko, D. R., Salmon, D. P., Sewell, D. D., Brewer, J. B., Feldman, H., Delano‐Wood, L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010643 · Cited by 47
Self-citationSundermann, E. E., Thomas, K. R., Bangen, K. J., Weigand, A. J., Eppig, J. S., Edmonds, E. C., Wong, C. G., Bondi, M. W., & Delano‐Wood, L. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.551975 · Cited by 47
Calvin, C. M., de Boer, C., Raymont, V., Gallacher, J., & Koychev, I. G. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00711-5 · Cited by 43
Zeng, Q., Li, K., Luo, X., Wang, S., Xu, X., Jiaerken, Y., Liu, X., Hong, L., Hong, H., Li, Z., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105755 · Cited by 44
Shaw, L. M. J., Hansson, O., Manuilova, E., Masters, C. L., Doecke, J. D., Li, Q.-X., Rutz, S., Widmann, M., Leinenbach, A., & Blennow, K. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.05.006 · Cited by 45
Self-citationKöbe, T., Gonneaud, J., Binette, A. P., Meyer, P., McSweeney, M., Rosa‐Neto, P., Breitner, J. C. S., Poirier, J., & Villeneuve, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20780 · Cited by 44
Duong, M. T., Das, S. R., Lyu, X., Xie, L., Richardson, H., Xie, S. X., Yushkevich, P. A., Initiative, A. D. N., Weiner, M. W., Aisen, P. S. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28941-1 · Cited by 44
Self-citationÖhrfelt, A., Benedet, A. L., Ashton, N. J., Kvartsberg, H., Vandijck, M. L. J., Weiner, M. W., Trojanowski, J. Q., Shaw, L. M. J., Zetterberg, H., Blennow, K., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201417 · Cited by 44
Self-citationWang, S., Deng, R., Chen, Z., Huang, L., Song, Y., Yuan, D., Li, Y., Liu, H., Yang, F., Fan, B., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c09311 · Cited by 44
Schöll, M., Vrillon, A., Ikeuchi, T., Quevenco, F. C., Iaccarino, L., Vasileva-Metodiev, S. Z., Burnham, S. C., Hendrix, J. A., Epelbaum, S., Zetterberg, H., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100056 · Cited by 48
Self-citationPre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
Hansson, O., Rutz, S., Zetterberg, H., Bauer, E., Hähl, T., Manuilova, E., Mert, M. C., Wahl, S., Blennow, K., & Stomrud, E. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12137 · Cited by 43
Self-citationCurrent research status of blood biomarkers in Alzheimer’s disease: Diagnosis and prognosis
Feng, L., Li, J., & Zhang, R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101492 · Cited by 45
Leuzy, A., Mattsson, N., Cullen, N. C., Stomrud, E., Palmqvist, S., Joie, R. L., Iaccarino, L., Zetterberg, H., Rabinovici, G. D., Blennow, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12897 · Cited by 46
Self-citationAdvances in blood biomarkers for Alzheimer disease ( AD ): A review
Assfaw, A. D., Schindler, S. E., & Morris, J. C. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12870 · Cited by 45
Amyloid-β as a Blood Biomarker for Alzheimer’s Disease: A Review of Recent Literature
Wang, X., Sun, Y., Li, T., Cai, Y., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190714 · Cited by 41
Brainstem Volumetric Integrity in Preclinical and Prodromal Alzheimer’s Disease
Dutt, S., Initiative, A. D. N., Li, Y., Mather, M., & Nation, D. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200187 · Cited by 46
Self-citationVisit-to-visit Blood Pressure Variability and Regional Cerebral Perfusion Decline in Older Adults
Sible, I. J., Yew, B., Dutt, S., Bangen, K. J., Li, Y., & Nation, D. A. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.009 · Cited by 42
Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline
Lan, G., Cai, Y. Q., Li, A., Liu, Z., Ma, S., Guo, T., & Initiative, A. D. N. (2022) · Annals of Neurology · doi:10.1002/ana.26492 · Cited by 42
Self-citationInteraction of amyloid and tau on cortical microstructure in cognitively unimpaired adults
Vogt, N. M., Hunt, J. F. V., Adluru, N., Ma, Y., Hulle, C. A. V., Dean, D., Kecskemeti, S., Chin, N. A., Carlsson, C. M., Asthana, S., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12364 · Cited by 42
Self-citationSible, I. J., Nation, D. A., & Initiative, O. B. O. A. D. N. (2022) · Neurology · doi:10.1212/wnl.0000000000200302 · Cited by 42
Hey, J. A., Abushakra, S. R., Blennow, K., Reiman, E. M., Hort, J., Prins, N. D., Sheardová, K., Kesslak, P. J., Shen, L. Z., Zhu, X., et al. (2024) · Drugs · doi:10.1007/s40265-024-02067-8 · Cited by 47
Self-citationQiang, Q., Skudder‐Hill, L., Toyota, T., Wei, W., & Adachi, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-20324-2 · Cited by 40
Sala, A., Nordberg, A. K., Rodriguez‐Vieitez, E., & Initiative, A. D. N. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00950-w · Cited by 43
Self-citationVascular risk burden is a key player in the early progression of Alzheimer’s disease
Ferrari‐Souza, J. P., Brum, W. S., Hauschild, L. A., Ros, L. U. D., Ferreira, P. C. L., Bellaver, B., Leffa, D. T., Bieger, A., Tissot, C., Lussier, F. Z., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.12.008 · Cited by 40
Self-citationHeo, G., Xu, Y., Wang, E., Ali, M., Oh, H. S., Losada, P. M., Anastasi, F., Escalante, A. G., Puerta, R., Song, S., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00872-8 · Cited by 51
Biofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias
Zetterberg, H., & Bendlin, B. B. (2026) · Nature · doi:10.1038/s41586-025-10018-w · Cited by 45
Self-citationClinical criteria for a limbic-predominant amnestic neurodegenerative syndrome
Corriveau‐Lecavalier, N., Botha, H., Graff‐Radford, J., Switzer, A. R., Przybelski, S. A., Wiste, H. J., Murray, M. E., Reichard, R. R., Dickson, D. W., Nguyen, A. T., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae183 · Cited by 47
Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease
Podlesniy, P., Llorens, F., Puigròs, M., Serra, N., Falla, D. S., Schmidt, C., Hermann, P., Zerr, I., & Trullás, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176298 · Cited by 38
Tangen, G. G., Nilsson, M. H., Stomrud, E., Palmqvist, S., & Hansson, O. (2022) · Neurology · doi:10.1212/wnl.0000000000201106 · Cited by 39
Self-citationYu, P., Shen, L., & Tang, L. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1609793 · Cited by 37
Llibre‐Guerra, J. J., Li, Y., Schindler, S. E., Gordon, B. A., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., Hassenstab, J. J., Wang, G., Allegri, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17126 · Cited by 40
Alzheimer’s Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy – Bridging the Missing Link
Hu, J., & Wang, X. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.811852 · Cited by 42
Lorenzini, L., Maranzano, A., Ingala, S., Collij, L. E., Tranfa, M., Blennow, K., Perri, C. D., Foley, C., Fox, N. C., Frisoni, G. B., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209801 · Cited by 36
Self-citationCaldwell, J., Cummings, J. L., Banks, S. J., Palmqvist, S., & Hansson, O. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0565-1 · Cited by 38
Self-citation
Metadata
- Authors
- Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., Buck, K., Zink, K., Rabe, C., Blennow, K., Shaw, L. M., for the Swedish BioFINDER study group, & Initiative, A. D. N.
- Affiliations
- Lund University (SE)
- Institute for Neurodegenerative Disorders (US)
- Sahlgrenska University Hospital (SE)
- University of Pennsylvania (US)
- Former Employee of Roche Diagnostics GmbH Penzberg Germany
- Roche Diagnostics GmbH Penzberg Germany
- F. Hoffmann-La Roche AG (CH)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Corresponding author
- Hansson, Oskar
- Blennow, Kaj
- Shaw, Leslie M.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2018-02-27
- Volume
- 14
- Issue
- 11
- Pages
- 1470-1481
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC6119541
- OpenAlex
- W2789976306
- Cited by
- 808
- References
- 45
- Citations by year
- 2026: 84 · 2025: 117 · 2024: 146 · 2023: 96 · 2022: 98 · 2021: 95 · 2020: 97 · 2019: 56 · 2018: 15
- FWCI
- 51.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Eli Lilly and Company
- Göteborgs Universitet
- National Institutes of Health
- National Institute on Aging (P30AG010124)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers
- MeSH terms
- Aged, Alzheimer Disease, Aniline Compounds, Ethylene Glycols, Female, Humans, Immunoassay, Male, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Radiopharmaceuticals, Positron-Emission Tomography, Automation, Laboratory, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
